| Identification | Back Directory | [Name]
NMDAR antagonist 1 | [CAS]
2220162-06-9 | [Synonyms]
NMDAR antagonist 1
Pyrrolo[2,1-b]quinazoline-1-carboxamide, 7-bromo-1,2,3,9-tetrahydro-N-[2-(4-hydroxyphenyl)ethyl]-, (1S)- | [Molecular Formula]
C20H20BrN3O2 | [MDL Number]
MFCD32173677 | [MOL File]
2220162-06-9.mol | [Molecular Weight]
414.3 |
| Chemical Properties | Back Directory | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO : 5 mg/mL (12.07 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
10.01±0.15(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
NMDAR antagonist 1 is a potent and orally bioavailable NR2B-selective NMDAR antagonist[1]. | [References]
[1] Zhang L, et al. Design, synthesis and bioevaluation of 1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline-1-carboxylic acid derivatives as potent neuroprotective agents. Eur J Med Chem. 2018 May 10;151:27-38. DOI:10.1016/j.ejmech.2018.03.052 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|